Marcelo Soto

Marcelo Soto

Auto-generated profile, based on publicly available information

Marcelo Soto

Fundació Clínic per a la Recerca Biomèdica, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2007 in Journal of Economic Growth
Verified
Journal Article
Closed access
PDF file
DCDaniel Cohen
Daniel Cohen
MSMarcelo Soto
Marcelo Soto

1 January 2001 in International Finance
Verified
Journal Article
Closed access
PDF file
HRHelmut Reisen
Helmut Reisen
MSMarcelo Soto
Marcelo Soto

1 January 1998 in Empirica
Verified
Journal Article
Closed access
PDF file
SVSalvador Valdés-Prieto
Salvador Valdés-Prieto
MSMarcelo Soto
Marcelo Soto

20 January 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MSMarcelo Soto
Marcelo Soto
LSLaura Sampietro-Colom
Laura Sampietro-Colom
AVAnna Vilella
Anna Vilella
EPEfrain Pantoja
Efrain Pantoja
MAMaría Asenjo
María Asenjo
MMmaria angeles Marcos
maria angeles Marcos
Seasonal influenza causes significant morbidity and mortality and has a substantial economic impact on the healthcare system. The main objective of this study was to compare the cost per patient for a rapid commercial PCR assay (Xpert® Flu) with an in-house real-time PCR test for detecting influenza virus. Community patients with influenza like-illness attending the Emergency Department (ED) as well as hospitalized patients in the Hospital Clínic of Barcelona were included. Costs were evaluated from the perspective of the hospital considering the use of resources directly related to influenza testing and treatment. For the purpose of this study, 366 and 691 patients were tested in 2013 and 2014, respectively. The Xpert® Flu test reduced the mean waiting time for patients in the ED by 9.1 hours and decreased the mean isolation time of hospitalized patients by 23.7 hours. This was associated with a 103€ (or about $113) reduction in the cost per patient tested in the ED and 64€ ($70) per hospitalized patient. Sensitivity analyses showed that Xpert® Flu is likely to be cost-saving in hospitals with different contexts and prices.

29 May 2003 in Journal of Development Economics
Verified
Journal Article
Closed access
MSMarcelo Soto
Marcelo Soto

1 January 2017 in World Journal of Gastroenterology
Verified
Journal Article
Open access
MSMarcelo Soto
Marcelo Soto
LSLaura Sampietro-Colom
Laura Sampietro-Colom
LLLuis Lasalvia
Luis Lasalvia
AMAurea Mira
Aurea Mira
WJWladimiro Jiménez
Wladimiro Jiménez
MNMiquel Navasa
Miquel Navasa
To assess liver fibrosis (LF) in hepatitis C virus (HCV) and alcoholic liver disease (ALD), estimate health outcomes and costs of new noninvasive testing strategies A Markov model was developed to simulate LF progression in HCV and ALD for a cohort of 40-year-old men with abnormal levels of transaminases. Three different testing alternatives were studied: a single liver biopsy; annual Enhanced liver fibrosis (ELF™) followed by liver stiffness measurement (LSM) imaging as a confirmation test if the ELF test is positive; and annual ELF test without LSM. The analysis was performed from the perspective of a university hospital in Spain. Clinical data were obtained from published literature. Costs were sourced from administrative databases of the hospital. Deterministic and probabilistic sensitivity analyses were performed. In HCV patients, annual sequential ELF test/LSM and annual ELF test alone prevented respectively 12.9 and 13.3 liver fibrosis-related deaths per 100 persons tested, compared to biopsy. The incremental cost-effectiveness ratios (ICERs) were respectively €13400 and €11500 per quality-adjusted life year (QALY). In ALD, fibrosis-related deaths decreased by 11.7 and 22.1 per 100 persons tested respectively with sequential ELF test/LSM and annual ELF test alone. ICERs were €280 and €190 per QALY, respectively. The use of the ELF test with or without a confirmation LSM are cost-effective options compared to a single liver biopsy for testing liver fibrosis in HCV and ALD patients in Spain.